We demonstrates that PIM2 mediates PFKFB3 phosphorylation thus regulates glycolysis and paclitaxel resistance to promote tumor progression in breast cancer, and provides preclinical evidence for targeting PFKFB3 as a new strategy in breast cancer treatment to battle paclitaxel resistance. Here, PIM2 is linked to breast cancer.